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Abstract 
Rationale Chronic obstructive pulmonary disease (COPD) has been identified as a risk factor 
for cardiovascular diseases such as myocardial infarction. The role of COPD in 
cerebrovascular disease is, however, less certain: although earlier studies have suggested 
that the risk for stroke is also increased in COPD, more recent investigations have generated 
mixed results.   
Objectives The primary objective of our review was to quantify the magnitude of the association 
between COPD and stroke. We also sought to clarify the nature of the relationship between COPD 
and stroke by investigating whether the risk of stroke in COPD varies with age, sex, smoking history 
and/or type of stroke and whether stroke risk is modified in particular COPD phenotypes. 
Methods A search of MEDLINE and EMBASE databases was conducted in May 2016 to 
identify articles which compared stroke outcomes in people with and without COPD. Studies 
were grouped by study design to distinguish those which reported prevalence of stroke 
(cross-sectional studies) from those which estimated incidence (cohort or case–control 
studies). Additionally, studies were stratified according to study population characteristics, 
the nature of COPD case definitions, and adjustment for confounding (smoking). 
Heterogeneity was assessed using the I2 statistic. 
Results We identified 5,484 studies, of which 30 met our pre-defined inclusion criteria. Of 
the 25 studies which reported prevalence ratios, 11 also estimated prevalence odds ratios 
(PORs). The level of heterogeneity among these cross-sectional studies did not permit the 
calculation of pooled ratios, save for a group of four studies which estimated prevalence 
odds ratios adjusted for smoking (POR=1.51; 95%CI: 1.09–2.09; I2=45%). All 11 studies which 
estimated relative risk for non-fatal incident stroke reported increased risk in COPD. 
Adjustment for smoking invariably reduced the magnitude of the associations. 
Conclusion Although both prevalence and incidence of stroke is increased in people with COPD, 
the weight of evidence does not support the hypothesis that COPD is an independent risk factor for 
stroke. The possibility remains that COPD is causal in certain subsets of COPD patients and for 
certain stroke subtypes. 
334 words  
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Introduction 
Comorbidities are highly prevalent in chronic obstructive pulmonary disease (COPD) and an 
important consideration in the management of this heterogeneous disease.  More than 95% of 
people with COPD have at least one comorbidity and over 50% have four or more (1). Cardiovascular 
diseases (CVDs) rank among the most frequently observed comorbidities in the COPD population 
and contribute to disease progression, poor clinical outcomes and mortality (2).  
 Large population-based studies have shown that CVD is not only a common cause of 
mortality in people with COPD, accounting for up to a third of all deaths (3), but also that the risk of 
cardiovascular mortality in this population is approximately twice that in the general population (4). 
Although the underlying reasons are not yet fully understood, there is evidence to suggest that  
COPD is an independent risk factor for the development of cardiovascular disease, with systemic 
inflammation providing the mechanistic link between the two (5-7).  
 The relationship between COPD and individual CVD outcomes has been the subject of 
several reviews (8-11). Whereas collective evidence points to an approximately twofold increase in 
the risk of a myocardial infarction (MI) (8, 11) the nature of the association between COPD and 
stroke is less certain. Earlier study findings are suggestive of an increased risk for stroke in people 
with COPD (12, 13), but more recent investigations have generated contradictory results (14). In 
order to clarify the role of COPD in relation to stroke, we performed a further systematic review of 
the available evidence linking COPD and stroke outcomes in which we report results separately for 
cross-sectional study designs (which estimate prevalence) and longitudinal cohort studies (which 
estimate incidence). In addition, we have been able to include a number of recently published 
population-based studies which investigate, in more detail than before, stroke outcomes by subtype.    
 
Methods 
Protocol and registration 
In accordance with the PRISMA-P guidelines (15), study objectives, inclusion criteria, search 
strategies and analysis methods were pre-specified and documented in a protocol, which was 
registered with the International Prospective Register of Systematic Reviews in March 2016 
(PROSPERO registration number: CRD42016035932) and published in the open literature (16). 
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Study objectives 
Our primary objective was to quantify the magnitude of the association between COPD and stroke. 
Secondary objectives were to determine:  1) whether there is any evidence that the association 
between COPD and stroke varies with age, sex, smoking history and/or type of stroke (e.g. 
haemorrhagic versus ischaemic); and 2) whether stroke risk is modified in particular COPD 
phenotypes, e.g. frequent exacerbators.  
 
Information sources and search strategy 
MEDLINE (OVID(R) interface, 1948 onwards) and EMBASE (Ovid interface, 1980 onwards) were 
searched in May 2016 for articles of potential relevance. Literature search strategies were developed 
using both Medical Subject Headings (MeSH terms) and free text searching using an appropriate set 
of key words to delimit the concepts “COPD” or “airflow limitation” and “stroke”. These searches 
were combined using the AND Boolean logic operator. The database search was supplemented by a 
manual scan of the reference lists of included studies. The search strategies are detailed in the data 
supplement (see e-Appendix 1).   
 
Eligibility criteria 
Inclusion criteria were drawn up using the PECOs framework.  We included observational studies 
which 1) employed either a cross-sectional, cohort or case–control design; 2) were conducted in an 
adult population aged > 35 years; and 3) reported prevalence and/or incidence of cerebrovascular 
events (stroke) in people with a diagnosis of COPD or evidence of obstructed lung function 
(FEV1/FVC ratio < 0.7) and also in a comparator group of individuals without COPD and/or with 
normal lung function. We also considered secondary analyses of randomised control trials where 
these met our other inclusion criteria. Accepted definitions for COPD included a physician diagnosis, 
recording of appropriate ICD-9/ICD-10 codes in healthcare databases, spirometry and self-report. 
We excluded abstracts, case histories, reviews and commentaries. No language restrictions were 
applied.  
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Study selection 
Titles and abstracts of all records identified by the database searches were screened by two 
reviewers. Full texts were retrieved for all titles potentially meeting the pre-defined eligibility 
criteria. Full-text screening was also conducted by two reviewers. Discrepancies were resolved by 
discussion with a third reviewer. 
 
Data extraction and quality assessment 
Information about study aims, design and setting, characteristics of the study population, COPD and 
stroke case ascertainment, as well as reported effect measures for the association between COPD 
and stroke outcomes were extracted for all included studies using a pre-designed form. Online 
supplementary material was consulted when necessary, and original authors were contacted to 
clarify and/or obtain numerical data as required.  
 Included studies were assessed for risk of bias using a tool adapted from the Newcastle–Ottawa 
scale (17) by the investigators to suit the purposes of this review. The adapted tool (see e-Appendix 2) 
was structured around the three main sources of bias in our included studies: selection of participants; 
measurement of variables (exposures, outcomes and covariates); and control of confounding. Each 
domain comprised several items, tailored where appropriate to take account of different study designs. 
Each item was assigned a risk of bias category as follows: “moderate-to-high risk of bias”, “unclear risk of 
bias” or “low risk of bias”. Risk of bias assessment was conducted independently by two reviewers on a 
subset of studies to check the internal validity and consistency of the tool.  
 
Analysis methods  
The included studies were grouped according to study design to distinguish studies which estimated 
prevalence of stroke events in people with COPD versus people without COPD (as a simple 
percentage or as a prevalence odds ratio (POR)) from those using either a cohort or case–control 
design to calculate the incidence of stroke, again comparing COPD with COPD-free individuals (as an 
odds ratio (OR), an incident rate ratio (IRR) or a hazard ratio (HR)). We further grouped studies 
according to the study population characteristics (general population versus secondary care), the 
nature of the quality of the exposure case definition (e.g. physician-diagnosed COPD versus self-
reported COPD), and the level of control for confounding (i.e. whether or not effect estimates had 
been adjusted for smoking). Several included studies reported multiple measures and/or conducted 
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more than one type of analysis, and these are presented separately. The risk of bias assessment was 
also conducted separately for each analysis type. 
 Heterogeneity was assessed by means of the I2 statistic. Given the high level of statistical 
heterogeneity, it was not deemed appropriate to calculate pooled effect estimates. A narrative 
synthesis was thus conducted.  
 
Results 
Study selection and characteristics 
A total of 5,484 articles of potential interest were identified by the database searches (Figure 1). 
After title and abstract screening, 305 articles, plus another 9 titles identified from reference lists of 
selected studies, were selected for full-text review. A total of 284 articles were subsequently 
rejected, leaving 30 studies to form the basis of this review. Table 1 (13, 14, 18-40) summarises the 
key characteristics of those studies which report prevalence measures and Table 2 (13, 14, 23, 37, 
39, 41-45) those which estimate incidence. Fuller information is provided in the data supplement (e-
Appendix 3). 
 
Prevalence of stroke events   
Twenty-five studies compared the frequency of stroke events in people with COPD with that in a 
comparator cohort of individuals without COPD (21 studies) or relative to a general or standard 
population (4 studies) using a cross-sectional study design; of these, 11 also reported crude or 
adjusted PORs (Table 1).  The majority of the included cross-sectional studies indicated that 
stroke events are more prevalent in people with COPD than in the general population (Figure 2). 
Only three studies (19, 34, 40) suggest otherwise. Of the 10 studies that reported prevalence ratios 
(PRs) in excess of 2, three were conducted in outpatient populations (18, 24, 32) and another two 
were based on self-reported diagnoses of both COPD and stroke (22, 25). Of the 11 studies that also 
reported PORs, 7 found a significantly increased odds of a stroke event in people with COPD relative 
to those without (Figure 3). PORs ranged in magnitude from 3.34 (95%CI: 3.21–3.48) to 1.05 (95%CI: 
0.63–1.77). While the majority of these studies reported effect estimates adjusted for age and sex, 
only four adjusted for smoking (Figure 3). 
Page | 7 
 
 The level of heterogeneity among studies reporting prevalence ratios was too large to justify 
reporting a pooled effect estimate (Figure 2), even when studies were further stratified (see e-
Appendix 4). However, heterogeneity was lower among the group of four studies which report PORs 
adjusted for smoking (I2=45%), implying that smoking may be an important source of the observed 
heterogeneity. The pooled prevalence OR for this group of studies was estimated at 1.51 (95%CI: 
1.09–2.09).  
Risk of incident stroke   
Eleven studies provided estimates of the relative risk of incident stroke in COPD (Table 2); of these, 
three reported IRRs, seven reported HRs and two reported ORs (in which patients with a prior stroke 
history were excluded from the analysis). One study reported risk estimates for non-fatal and fatal 
stroke in the form of a standardised rate ratio (SRR for hospitalisation) and a standardised mortality 
rate (SMR), respectively (41). The majority of the older incidence studies reported effect estimates 
for any stroke event (a composite of ischaemic, haemorrhagic and “not specified” stroke); four 
estimated the relative risk of having a fatal stroke (23, 39, 41, 42). One study reported results for 
ischaemic strokes only (14). Several of the more recently published large population-based cohort 
studies estimated relative risks by stroke subtype (43,44,45). The effect of COPD disease severity 
was investigated in two studies (37,44). 
 Results of studies which estimated stroke risk in the form of IRRs or HRs are presented in 
Figure 4a, and those that reported either RRs, SRRs or ORs in Figure 4b, grouped according to 
whether effect estimates were adjusted for smoking. Collectively, these studies suggest an increased 
risk for incident stroke in people with COPD relative to those without. Effect estimates for all stroke 
ranged from 2.79 (95%CI: 2.56–3.04) to 1.11 (95%CI: 1.02–1.21), but the high degree of 
heterogeneity prohibited pooling of estimates (I2>70%). Adjustment for smoking invariably reduced 
the strength of the association between COPD and stroke; among those studies which reported 
results unadjusted and adjusted for smoking, unadjusted effect estimates ranged from 1.20 (95% CI: 
1.00–1.43) to 2.79 (95% CI: 2.56–3.04) whereas adjusted effect estimates ranged from 1.09 (95% CI: 
0.91–1.31) to 1.62 (95% CI: 1.49–1.77). Moreover, in three of five studies (23,37,44) adjustment for 
smoking not only reduced the magnitude of the relative risk but the effect estimates lost statistical 
significance.  
 A number of studies reported effect estimates stratified by either age or gender, or both 
(13,39,45). These analyses suggested that the effect of COPD on the risk of incident stroke is higher 
for women and in younger age groups (under 65s). The study by Feary et al., 2010 (13) for example 
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reported an adjusted HR for stroke of 3.44 (95% CI: 0.85–13.84) in subjects aged 35–44 years (the 
youngest age group) and a steady reduction in the relative risk for stroke with increasing age, down 
to 1.10 (95% CI: 0.98–1.23) among the over 75s (Figure 4b).   
 Three studies reported effect estimates by stroke subtype (43-45). Two reported a greater 
relative risk for haemorrhagic stroke compared with ischaemic stroke (Figure 5). Soderholm et al. 
(2016) found that the greatest risk was for subarachnoid haemorrhage (SAH) [HRSAH=1.46; 95%CI, 
1.16–1.85; HRICH=1.29; 95%CI, 1.16–1.43; HRIS=1.20; 95%CI, 1.15–1.25], the risk for which did not 
diminish over the 10 years of follow up, unlike that for ischaemic stroke (IS) and intracerebral 
haemorrhagic (ICH)  stroke which was greatest during the initial two-year period of follow up (45). In 
contrast, Lin et al. (2015) reported HRs for ischaemic and haemorrhagic stroke of 1.64 (95%CI, 1.49–
1.82) and 1.18 (95%CI, 0.89–1.57), respectively (43).  
 None of our included studies found evidence of a relationship between COPD disease 
severity and stroke risk (37,44). Only Portegies et al. investigated the influence of exacerbation 
frequency on stroke risk and reported no difference in risk between frequent and infrequent 
exacerbators (44). They did however observe a significantly increased risk for stroke in the 7-week 
period immediately after the onset of a severe acute exacerbation of COPD [adjusted HR=6.6 
(95%CI, 2.42–18.2)].  
 
Risk of bias assessment  
Figure 6 summarises the results of the risk of bias assessment, displaying  for each of the study 
design categories the proportion of analyses assessed as having a low risk of bias (green) and a 
moderate-to-high risk of bias (red). Results for individual studies are provided in the supplementary 
material (see e-Appendix 5). Cross-sectional studies rated reasonably well in terms of the selection 
of the exposed and unexposed groups but a relatively high proportion of studies relied on self-report 
and/or were unclear as to whether TIAs were included in the definition of “any stroke”. A significant 
number were conducted in hospital populations, involving smaller sample sizes and thus fewer 
stroke events. For the group of incidence studies, the main biases stemmed from the poor control of 
confounding, of smoking in particular, and the length of follow up. 
 
Discussion  
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This systematic review finds that strokes are more common in people with COPD than in the general 
population, and that the risk of experiencing an incident stroke is increased in people with COPD. 
Although the high level of heterogeneity limited our ability to quantify the magnitude of the 
increased risk of incident stroke, we suggest that this is relatively modest, and less than that 
reported for other cardiovascular outcomes such as MI.   
 The fact that the magnitude of the association between COPD and stroke is attenuated by 
adjustment for smoking implies that this shared risk factor accounts for much of the elevated risk 
and that COPD by itself does not confer a large additional risk. Only 2 of the 11 analyses which 
estimated risk of incident stroke lend support to the hypothesis that COPD is an independent risk 
factor for stroke (13, 43),  and indicates there is heterogeneity in the causal mechanisms underlying 
the association between COPD and specific cardiovascular diseases.  
 We found evidence to suggest that the relative risk for stroke declines with increasing age, 
with the greatest risk occurring in those COPD patients aged under 65 years. There is also some 
evidence, albeit limited at the present time due to the paucity of studies, that the relative risk for 
haemorrhagic stroke may be greater than that for ischaemic stroke (44,45). A heightened risk of 
haemorrhagic stroke, and SAH in particular, is consistent with reports of an increased presence of 
cerebral small vessel disease in people with COPD, and implies a role for hypoxia and oxidative stress 
in the pathophysiology of stroke in COPD (46-48). In this context, it is interesting to note that Arboix 
et al. in their study of stroke registry patients identified COPD as an independent risk factor for 
ischaemic strokes of atherothrombotic origin (OR=1.40; 96%CI: 1.04–1.93) but not for other types of 
ischaemic stroke (e.g. lacunar and cardioembolic strokes)(49, 50). While this is consistent with the 
increased burden of carotid artery plagues of high lipid content seen in people with COPD (46), we 
are unable to corroborate this finding due to the lack of studies which examine ischaemic stroke 
outcomes by subtype.  
 We found no clear evidence that COPD disease severity influences stroke risk (independently 
of age). However, the role of exacerbations remains a matter of some debate and warrants further 
investigation. Two studies failed to find an association between exacerbation frequency and stroke 
risk ,(44, 51),  but others have reported markedly increased risks for stroke in the period immediately 
following an acute exacerbation relative to periods of more stable disease,(44, 52).  
 Our review serves to highlight several intriguing features of the evidence base linking COPD 
and stroke. The first is the differential in risk for MI and stroke in COPD (14). While a degree of 
heterogeneity in the magnitude of the associations between COPD and individual CVDs due to 
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aetiologic differences is to be expected (53), other factors – such as competing risks – may well be 
contributing to the observed differential. It is also possible that treatment initiated for early cardiac 
disease may be preventing subsequent strokes in the COPD population (44).  
 The second is the observation that while several population-based studies have 
demonstrated an inverse relationship between lung function impairment as measured by FEV1 (% 
predicted) and stroke risk (54-59), few find evidence of a similar relationship with low FEV1/FVC, a 
measure which is indicative of airflow obstruction and thus COPD. For example, Howaza et al. 
(2006), using data from the Atherosclerotic Risk In Communities Study (ARIC) showed that non-
smoking white subjects with low FEV1 (and FVC) were at increased risk of ischaemic stroke; however 
there was no evidence of an association with the ratio, FEV1/FVC (56). This finding highlights the 
need for more research to identify which aspects of impaired lung function are the most important 
in terms of CVD risks and to characterise the groups at greatest risk. The observed link between FEV1 
and vascular disease may, as some have suggested, imply a role for common early life determinants 
(60). Alternatively, in terms of the development of vascular and airways disease, events in later life 
may be more relevant.  Several studies have demonstrated increased risks for stroke in subjects with 
chronic bronchitis (61, 62). This coupled with evidence for increased risk for stroke in the period 
following a severe exacerbation of COPD might imply that those with more bronchitic COPD, who 
experience frequent exacerbations and steeper rates of lung function decline, might be at 
heightened risk for ischaemic stroke. 
 
Strengths and limitations  
While the present review benefits from the adoption of a comprehensive search strategy and broad 
inclusion criteria, there are limitations. The main limitation is the high level of heterogeneity in the 
included studies, which precludes the calculation of an overall effect estimate.  
 The main sources of heterogeneity are differences in study population characteristics, 
coupled with variations in case definitions for both the exposure and outcomes. Studies sourcing 
individuals from secondary care are likely to have a higher proportion of patients more severe 
disease and are unlikely to be representative of the COPD patient population as a whole. Case 
definitions for COPD are highly heterogeneous, ranging from self-report to pulmonary physician 
diagnoses supported by spirometry. Misclassification of COPD with asthma is likely to represent a 
significant source of bias, even in studies which purport to use physician diagnoses. Although self-
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reported stroke diagnoses might be considered to be more reliable than those for COPD, studies are 
inconsistent in their definitions of all stroke and stroke subtypes.  
 The lack of adequate control for confounding, in particular smoking, represents another 
inherent limitation. Our review includes a number of studies which rely on administrative health 
care databases, the majority of which do not contain data on smoking. Given that many of our 
included studies investigated multiple CVD outcomes, not just stroke, we judge the risk of 
publication basis to be low.  
 
Conclusion  
Both prevalence and incidence of stroke is increased in people with COPD. The increased risk for 
incident stroke is attenuated by adjustment for smoking, suggesting that in the population as a 
whole COPD is not an independent risk factor for stroke. However, the possibility remains that COPD 
is a causal factor in certain subsets of COPD patients, and for certain types of stroke. Our review 
highlights the need for further well controlled and detailed longitudinal cohort studies in order to 
quantify the nature and magnitude of the risk of different stroke subtypes in people with COPD.  
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Table 1: Key characteristics of included studies: prevalence 
Study Study design 
and setting 
Study 
population 
COPD Stroke 
outcome  
Stroke prevalence 
(%) COPD v non-
COPD unless 
otherwise stated 
PR and/or maximally 
adjusted POR (95% CI) 
COPD v non-COPD 
unless otherwise stated 
No. of 
subjects 
Men 
 (%) 
Agusti et al., 
2010 (18) 
x-sectional  
Multi-country 
Hospital outpatients 
(ECLIPSE study cohort) 
2,164 
 
65.3% 
   
Any stroke  4.0% v 1.7 % PR: 2.31 (1.2–4.4) 
Antonelli-
Incalzi et al.,  
2009 (19) 
Cohort  
Italy 
Hospital outpatients 
(SaRA study 
participants) 
238 81% Any stroke  2.3% v 7.0% (at 
baseline) 
PR: 0.34 (0.15–0.81) 
Bentsen et al., 
2011 (20) 
x-sectional  
Norway 
Hospital clinic 
attendees  
100 47% Any stroke  3.0% v 2.3% (COPD 
v general 
population) 
 PR: 1.33 (0.45–4.33) 
Cazzola et al., 
2012 (21) 
x-sectional 
Italy  
General population 
(Health Search 
Database)   
25,281 46% Any stroke  4.2% v 2.0%  PR: 2.05 (1.93–2.18) 
Adjusted POR (age only): 
3.60 (3.42–3.82)  
Cunningham 
et al., 2015 
(22) 
x-sectional 
health survey 
USA 
General population 
(2011 Behavioral Risk 
Factor Surveillance 
System survey 
participants) 
33,088 40% Any stroke  9.7% v 2.8% 
7.4% v 2.4%  ( 
COPD v age-
standardised 
population) 
PR: 3.46 (3.34–3.60)  
 
Curkendall et 
al., 2006 (23) 
 
Matched 
cohort  
Saskatchewan, 
Canada 
 
General population  
(administrative 
healthcare database)  
11,493 54% Any stroke  1. Baseline 
4.8% v 3.3%  
 
 
 
2. Period 
 9.6% v 7.9%  
1. Baseline 
PR: 1.45 (1.30–1.62)  
Adjusted POR (age, sex by 
matching): 1.47 (1.31–
1.64) 
  
2. Period 
PR: 1.22 ( 1.14–1.33)  
Adjusted POR (age, sex by 
matching): 1.24 (1.15–
1.34)  
de Lucas- 
Ramos et al., 
2012(24) 
Case–control 
Madrid, Spain 
Primary and secondary 
clinic attendees  
970 70.4% Any stroke  10.0%  v 2.9% 
 
PR: 3.45 (1.70–7.01) 
Adjusted POR (age, sex,  
HTN,HLD, DM,  smoking): 
3.22 ( 1.47–7.04) 
Feary et al.,  
2010 (13) 
Cohort 
UK 
General population 
(THIN  primary care 
database) 
29,870 48.1% Any stroke 
(inc TIAs) 
9.9% v 3.2%  (at 
baseline)  
 
PR: 3.1 (3.0–3.2) 
POR: 3.34 (3.21– 3.48) 
Finkelstein et 
al., 2009 (25) 
x-sectional 
health survey 
USA 
General population 
(2002 National Health 
Interview Survey)  
958 46% Any stroke  8.0% v 3.6%   
 
PR: 2.2 (1.78–2.80) 
Adjusted POR (SES, health 
behaviours, 
comorbidities): 1.5 ( 1.1–
2.1) 
Garcia-Olmos 
et al., 2013 
(26) 
x-sectional  
Madrid, Spain 
General population 
(primary care records) 
3,124 76% Any stroke  7.49% v 6.48% 
(COPD v  expected 
prevalence in 
general population) 
PR: 1.19 (0.89–1.42) 
Guerra et al., 
2010 (27)  
Cohort 
Tuscon, AR, 
USA 
General population 
(TESAOD study 
participants) 
294 53.1% Any stroke  3.1% v 1.1% (on 
enrolment) 
PR: 2.8 (1.22–6.02) 
Jo et al.,2015 
(28) 
 
Cross-sectional 
health survey 
Republic of 
Korea  
General population 
(KNHANES V survey 
respondents)  
744  100% 
 
Any stroke  2.7% v 1.9%  
2.1 % v 1.3% 
(population 
weighted) 
PR: 1.42 (0.86–2.32)  
Adjusted POR (age): 1.61 
(0.84–3.09) 
Page | 18 
 
Lin et al., 
2010 (29) 
 
Matched 
cohort 
Maryland, USA  
General population 
(Medicaid database) 
1,388 20.8% Any stroke  
 
10.7% v 6.5% (at 
baseline) 
PR: 1.65 (1.35–2.04) 
Adjusted POR (age, sex by 
matching) : 1.73 (1.38–
2.18)  
Lindberg et 
al., 2011 (30) 
Matched 
cohort 
Northern 
Sweden 
General population 
(OLIN study cohort)  
933  55% Any stroke  
 
7.7% v 7.1% (at 
baseline) 
 
 
PR: 1.08 (0.79–1.48) 
Adjusted POR (age, sex, 
BMI, smoking): 1.05 
(0.63–1.77) GOLD stage  
II-IV v no-COPD  
Lopez-Varela 
et al., 2013 
(31) 
x-sectional  
Five Latin 
American cities 
Population based 
(PLATINO study 
participants) 
759  
 
52% CVA 3.2% v 2.1% PR: 1.52 (0.96–2.33) 
Mapel et al., 
2000 (32) 
x-sectional  
(two cohorts) 
 
New Mexico,  
USA 
1. HMO  
General population 
(Lovelace Health Plan)  
2.UMC 
Hospital patients 
1. HMO 
200 
 
2. UMC 
200 
1. HMO 
51% 
 
2. UMC 
36% 
1. HMO 
Any stroke  
2. UMC 
Any  stroke  
1. HMO 
4.0% v 3.5%  
 
2. UMC 
6.5% v 2.8% 
1. HMO 
PR: 1.14 (0.42–3.09) 
 
2. UMC 
PR:2.3 (0.84–5.59) 
Mapel et al., 
2005 (33) 
x-sectional 
(two different 
time periods) 
New Mexico,  
USA 
Hospital inpatients 
(Veterans 
Administration System)  
1. 1992 
87,867 
 
2. 1998 
70,679 
1. 1992 
99% 
 
2. 1998 
98% 
Any  stroke 1. 1992 
7.5% v 6.8%  
 
2. 1998 
7.9% v 7.7%  
1. 1992 
PR: 1.1 (1.08–1.14) 
 
2. 1998 
PR:1.02 (0.97–1.03) 
Miniati et al., 
2014 (34) 
Matched 
cohort 
Pisa, Italy 
General population  200 89% Any stroke  1% v 1.5% PR: 0.66 (0.11–4.00) 
Nagorni-
Obradovic 
and Vukovic, 
2014 (35) 
x-sectional 
health survey 
Serbia  
General population 
(household health 
survey respondents) 
653 46.6% Any stroke  
 
5.4% v 3.8%  PR:1.42 (0.98–1.80) 
Adjusted POR (age, sex, 
education, smoking): 1.44 
(0.92–2.26) 
Pleasants et 
al., 2014 (36) 
x-sectional 
health survey 
North Carolina, 
USA 
General population 
(Behavioral Risk Factor 
Surveillance System 
survey participants) 
1,948 NR Any stroke  4.4% v 2.4% PR: 1.57 (1.16–2.13) 
Schneider et 
al., 2010 (37) 
Matched 
cohort 
UK 
General population 
(CPRD primary health  
care database)  
35,772  
 
 
51% Any stroke 
(inc TIAs) 
6.9% v 5.9% (at 
baseline) 
PR: 1.17 (1.12–1.24) 
Adjusted OR (age, sex, GP 
practice): 1.19 (1.12–1.26) 
Schnell et al., 
2012(38) 
x-sectional 
health survey 
USA 
General population 
(NHANES study 
participants) 
995 39.9% Any CVA 9.0% v 4.5% 
 
PR: 1.93 (1.57–2.40)  
 
Sidney et al., 
2005(39) 
Matched 
cohort   
North 
California, USA 
General population 
(NCKP Medical Care 
Program subscribers)  
45,966  
 
55.4%   Hospitalisa
tion for 
stroke  
  
1.2% v 0.5% (at 
baseline) 
 
PR: 2.4 (2.08–2.82) 
Adjusted POR (age, sex, 
length of subscription) : 
2.44 (2.09–2.85)  
Van Manen et 
al. 2001(40) 
x-sectional 
Western 
Netherlands 
General population 
(patients registered 
with 28 GP practices) 
290  64% Any CVA  
 
 
3.1% v 3.7%   
 
PR: 0.86 (0.39–1.96) 
Yin et al., 
2014 (14) 
Cohort 
Sweden 
General population 
(national administrative 
databases) 
51,348  44.3%  
 
Ischaemic 
stroke  
4.2% v 1.9% (COPD 
v general 
population)   
PR: 2.2 (2.07–2.32)  
COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular attack; DM, diabetes mellitus; HLD, hyperlipidaemia; 
HTN, hypertension; PR, prevalence ratio; POR, prevalence odds ratio: SES socioeconomic status 
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Table 2: Key characteristics of included studies: incidence 
Study  Study design 
and setting 
 
Study 
population   COPD 
Reported effect 
measures 
Maximally adjusted 
effect estimate 
(95% CI) COPD v 
non-COPD unless 
otherwise specified 
Factors adjusted for  
(maximally adjusted 
estimate) 
No. of 
subjects 
Men  
(%) 
 
Curkendall 
et al., 2006 
(23) 
 
Matched cohort, 
1998–2001  
Saskatchewan, 
Canada 
 
General 
population 
(administrative 
health care 
databases) 
11,493 54% 1. OR for any stroke 
  
2. IRR for 
hospitalisation  
3. IRR for fatal 
stroke 
1. Adjusted OR: 1.11 
(1.02–1.21) 
2. Adjusted IRR: 1.23 
(0.68–2.22) 
3. Adjusted IRR: 1.24 
(0.90–1.71) 
1. Age, sex (by matching) 
plus HTN, HLD, DM, CVDs 
2. Age, sex, HTN, HLD, DM, 
obesity, smoking, CVDs 
3. Age, sex (by matching) 
Feary et al.,  
2010 (13) 
Cohort,  
2005–2007 
UK 
General 
population (THIN 
primary health 
care databases) 
29,870 48.1% 
 
HR for any stroke 
(inc TIAs)   
Crude HR: 2.79 (2.56–
3.04) 
 
 
Guerra et al., 
2010 (27) 
 
Cohort,  
1972–1996 
Tuscon, AR,  
USA 
General 
population 
(TESAOD study 
participants) 
155 61.3% HR  for fatal stroke Adjusted HR:  6.2 
(2.9–13.4) recurrent 
obstructive v normal 
spirometry 
Age, sex, BMI 
Huiart et al., 
2005 (41) 
Cohort,  
1990–1999 
Saskatchewan, 
Canada 
 
General 
population 
(administrative 
healthcare 
databases) 
5,648 53.9% 1. SRR for 
hospitalisation  
2. SMR for fatal 
stroke 
1. SRR: 1.27 (1.16–
1.38) 
 
2. SMR:  1.60 (1.36–
1.85) 
Age, sex, calendar year by 
indirect standardisation 
using a standard population 
Knuiman et 
al., 1999 (42) 
Cohort,  
1969–1995 
Busselton, 
Australia 
General 
population 
(Busselton Health 
study 
participants) 
606 64% HR for fatal stroke, 
separately for men 
and women  
Men  
Adjusted HR: 0.76 
(0.39–1.47) 
Women 
Adjusted HR: 0.90 
(0.44–1.91) 
 
Age, smoking, %FEV1, other 
respiratory symptoms, CHD, 
CVD  risk factors 
 
Lin et al., 
2015 (43) 
Matched cohort, 
2004–2006  
Taiwan, Province 
of China 
General 
population 
(National health 
insurance 
database, 
LHID2005)  
 
10,413 65.8% 1. IRR for any 
stroke (exc TIAs) 
2. HR for any stroke 
(exc TIAs) 
1. Adjusted  IRR: 1.79 
(1.50–2.13) 
2. Propensity score 
adjusted HR: 1.62 
(1.49–1.77) 
1. age, sex (by matching) 
 
2. Matching variables plus 
HTN, HLD, DM , CHD,  
smoking, alcohol,  BMI 
Portegies  
et al., 
2015(44) 
Cohort, 1990–
2012 
Ommoord, 
Rotterdam, The 
Netherlands  
General 
population 
(Rotterdam Study 
participants) 
1,566 
 
53.5% 
 
HR for any stroke Adjusted HR: 1.09 
(0.91–1.31) 
 
Age, sex, smoking  
Schneider  
et al., 2010 
(37) 
Cohort, 1995–
2005 
UK 
General 
population (CPRD 
primary health 
care database) 
15,907 NR IRR for any stroke 
(inc TIA) 
Adjusted IRR: 1.23 
(0.79–1.92) 
Age, sex, GP practice (by 
matching)   
Schneider  
et al., 2010 
(37) 
Nested case–
control  
UK 
General 
population (CPRD 
primary health 
care database) 
NR NR OR for any stroke 
(inc TIA)  
Adjusted OR: 1.13 
(0.92–1.38) 
Age, sex, GP practice (by 
matching), plus smoking, 
BMI, HTN, DM, aspirin use 
Sidney et al., 
2005 (39) 
Matched cohort, 
1996–2000  
Northern 
California, USA 
Mixed (KPNC 
Medical Care 
Program 
subscribers)  
1,010 
 
54.4% 1. RR for 
hospitalisation  
2. RR for fatal 
stroke  
1. Adjusted RR: 1.39 
(1.25–1.54)   
2. Adjusted RR: 1.35 
(1.09–1.66) 
 
1. Age, gender, DM, HTN, 
HLD, prior  CVD 
2. Age, gender, DM, HTN, 
HLD, prior  CVD  
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Soderholm 
et al., 2016 
(45) 
Matched cohort, 
1996–2000 
Sweden 
Hospitalised 
population 
(Inpatient 
registers) 
103,419 54.2%  
 
HR for 
hospitalisation  
Adjusted HR: 1.24 
(1.19–1.28) 
SES, country of origin, 
history of asthma, DM, CVD, 
rheumatoid arthritis, kidney 
disease, lupus,  length of 
hospital stay 
Yin et al., 
2014 (14) 
Cohort, 2005–
2008 
Sweden  
General 
population 
(national 
administrative 
databases) 
51,348 44.3% HR for ischaemic 
stroke 
 
Fully adjusted HR: 
1.09 (1.02–1.17) 
 Age, sex, SES, medications 
COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular attack; DM, diabetes mellitus; HLD, hyperlipidaemia; 
HTN, hypertension; HR, hazard ratio; OR, odds ratio; IRR, incident rate ratio; RR, relative risk; SES socioeconomic status; 
SMR, standardised mortality ratio;  
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Figure 1. Flow chart of included studies  
Note: some studies were excluded for more than one reason.  
Records identified through  
database searching 
(n = 6,816 ) 
Additional records identified  
through other sources 
(n = 9) 
Records after duplicates removed 
(n = 5,484 + 9) 
Full-text articles assessed  
for eligibility 
(n = 314) 
Records excluded 
(n = 5,180) 
Full-text articles excluded: 
 Incorrect outcome (n = 64) 
 Incorrect exposure (n = 51) 
 Incorrect comparator (n = 21)  
 Incorrect study design  
(n = 32) 
 Incorrect population (n = 18) 
 Review article (n = 46) 
 Duplicate (n = 13) 
 Abstract only (n = 38) 
 Other (n = 26) 
Studies included in qualitative 
synthesis 
n = 30 
N=3- 
 
Records screened  
(title & abstract) 
(n = 5,493) 
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Figure 2: Forest plot showing estimates of the prevalence ratio (PR) for stroke comparing people 
with and without COPD  
 
Note: Subjects = number of study participants with COPD. 
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Figure 3: Forest plot showing estimates of the prevalence odds ratio (POR) for stroke comparing 
people with and without COPD, grouped according adjustment for smoking  
 
 
Note: Subjects = number of study participants with COPD. 
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Figure 4: Forest plot showing relative risks for stroke comparing people with and without COPD, 
grouped according adjustment for smoking  
a) IRRs/HRs  
 
b) RRs/ORs 
 
 Note: Subjects = number of study participants with COPD. 
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Figure 5: Relative risks for stroke, by stroke subtype  
 
Note: Subjects = number of study participants with COPD   
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Figure 6: Risk of bias assessment results for a) studies which estimate prevalence ratios, b) studies which 
prevalence odds ratios and c) studies which estimate incidence of stroke events in people with COPD versus 
people without COPD 
Figure 6a: Prevalence ratios (PR) 
 
Figure 6b: Prevalence odds ratios (POR) 
 
Figure 6c: Incidence (HR, IRR, OR, RR)  
 
Note: The signalling questions employed in the risk of bias assessment vary according to study type and are coded as 
follows: A1 relates to the representativeness of study population; A2 to the representativeness  of exposed individuals; A3 
to the representativeness/selection of unexposed individuals;  B1 to the ascertainment of exposure;  B2 to the assessment 
of the outcome; B3 to the length of follow up (long enough for outcomes to occur);  C1 to adjustment for confounding 
(appropriate);  C2 to the  sample size (adequate ); C3 to the absence or otherwise of the outcome at study start; and  C4 to 
missing data (appropriate handling) and D1 to other potential sources of bias of concern. See also e-Appendix 5). 
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